RRC ID 31723
Author Matsumoto S, Wakai Y, Nakai T, Hatano K, Ushitani T, Ikeda F, Tawara S, Goto T, Matsumoto F, Kuwahara S.
Title Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis.
Journal Antimicrob Agents Chemother
Abstract The efficacy of FK463, a novel water-soluble lipopeptide, was evaluated in mouse models of pulmonary aspergillosis and was compared with that of amphotericin B (AMPH-B). In the pulmonary aspergillosis models induced by intranasal inoculation, FK463 exhibited good efficacy, with 50% effective doses in the range of 0. 26 to 0.51 mg/kg of body weight; these values were comparable to those of AMPH-B. In an Aspergillus target organ assay with immunosuppressed mice, under conditions of constant plasma levels of FK463, using a subcutaneously implanted osmotic pressure pump, a significant reduction in viable fungal cells was observed at plasma FK463 levels of 0.55 to 0.80 microgram/ml or higher. We conclude that FK463 is highly effective in the treatment of pulmonary aspergillosis in this animal model. These results indicate that FK463 may be a potent parenterally administered antifungal agent for pulmonary aspergillosis.
Volume 44(3)
Pages 619-21
Published 2000-3-1
DOI 10.1128/AAC.44.3.619-621.2000
PMID 10681328
PMC PMC89736
MeSH Amphotericin B / therapeutic use Animals Antifungal Agents / therapeutic use* Aspergillosis / drug therapy* Aspergillosis / microbiology Aspergillus fumigatus / drug effects* Echinocandins Lipopeptides Lipoproteins / therapeutic use* Lung Diseases, Fungal / drug therapy* Lung Diseases, Fungal / microbiology Micafungin Mice Mice, Inbred ICR Microbial Sensitivity Tests Peptides, Cyclic / therapeutic use* Treatment Outcome
IF 4.904
Times Cited 74
Pathogenic microorganisms IFM 40814 IFM 41209